Pay in 4 interest-free payments of $6.00 Learn more
Ships within 48 hours · Estimated delivery Aug 17 - Aug 22
Liver fat reduction: the retatrutide advantage One area where the dosage comparison reveals a dramatic difference is liver fat reduction
The truth is simple
The decision tree is short: Under 86F for less than 21 days total: Use it
This single-pathway approach has strong clinical evidence: semaglutide achieved average weight loss of 15% in the STEP trials over 68 weeks
If you experience rash, hives, itchiness, shortness of breath, or other symptoms of an allergic reaction, please discontinue use immediately and consult your physician
In the SURPASS-CVOT trial, tirzepatide met its primary endpoint of non-inferiority to dulaglutide for MACE-3, though it lacks an FDA-approved MACE-reduction indication in the U.S.[2] Post hoc cardiorenal analyses examined outcomes beyond the primary MACE endpoint in patients with concurrent cardiovascular and renal risk [3]
US$ 20.40
US$ 24.53
US$ 27.97
